2139382-75-3 Usage
Uses
Used in Pharmaceutical Industry:
4-methyl-3-([4-(3-pyridyl)-2-pyrimidinyl]amino)-N-[5-(3-oxo-4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide is used as an impurity compound in the production of Nilotinib for the treatment of chronic myelogenous leukemia. Its presence is crucial for quality control and ensuring the purity of the medication.
Used in COVID-19 Research:
In the field of COVID-19 research, 4-methyl-3-([4-(3-pyridyl)-2-pyrimidinyl]amino)-N-[5-(3-oxo-4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide is used as a research product to explore its potential applications in understanding or combating the virus. Its role in this context is still under investigation, highlighting the ongoing efforts to discover new therapeutic agents or insights into the disease.
Check Digit Verification of cas no
The CAS Registry Mumber 2139382-75-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,1,3,9,3,8 and 2 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 2139382-75:
(9*2)+(8*1)+(7*3)+(6*9)+(5*3)+(4*8)+(3*2)+(2*7)+(1*5)=173
173 % 10 = 3
So 2139382-75-3 is a valid CAS Registry Number.
2139382-75-3Relevant academic research and scientific papers
Nilotinib oxidation degradation impurity and preparation method thereof
-
, (2017/10/07)
The invention discloses a nilotinib oxidation degradation impurity namely 4-methyl-3-[4-(3-pyridyl)-2-pyrimidinyl]amido-N-[5-(3-oxo-4-methyl-1H-imidazole-1-yl)-3-(trifluoromethy)phenyl]benzamide (I) and a preparation method thereof. The preparation method comprises the following steps: taking 3-(4-methyl-1H-1-imidazolyl)-5-trifluoromethyl aniline as the raw material, carrying out amino protection, oxidation, and hydrolysis de-protection to obtain 3-(3-oxo-4-methyl-1H-1-imidazolyl)-5-trifluoromethyl aniline, and carrying out condensation reactions between 3-(3-oxo-4-methyl-1H-1-imidazolyl)-5-trifluoromethyl aniline and 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amido]benzoic acid to obtain the nilotinib oxidation degradation impurity (I). The discovery and preparation of the impurity have an important meaning for the quality research and quality improvement of nilotinib and promote the development of nilotinib.
